News & HighlightsNews
The Rockefeller University releases statement concerning Knut Wittkowski
The opinions that have been expressed by Knut Wittkowski, discouraging social distancing in order to hasten the development of herd immunity to the novel coronavirus, do not represent the views of The Rockefeller University, its leadership, or its faculty.
Rockefeller scientists launch a broad range of studies into novel coronavirus
Over 130 scientists in 18 labs are conducting research to advance the development of new, urgently needed approaches for the prevention and treatment of COVID-19.
Elaine Fuchs awarded 2020 Canada Gairdner International Award for Biomedical Science
Fuchs, a world leader in the study of skin biology, is being recognized for revealing the molecular mechanisms by which skin stem cells make and repair tissues.
How skin cells embark on a swift yet elaborate death
Scientists have identified the mechanism that allows skin cells to sense changes in their environment, and very quickly respond to reinforce the skin's outermost layer. The findings provide insight into how errors in this process might lead to skin conditions like psoriasis.  
Research on soldier ants reveals that evolution can go in reverse
Turtle ant soldiers and their oddly-shaped heads suggest that evolution is not always a one-way street toward increasing specialization.
Paul Muller wins 2020 Weintraub Graduate Student Award
Muller receives the honor for his examination of the interactions between neurons in the intestinal tract, known as enteric neurons, and intestinal macrophages, a kind of immune cell.
Rockefeller gets a new, more efficient boiler
With the aid of a mobile crane and a crew of around 20, a fully assembled Cleaver Brooks Fire Tube boiler was delivered into the university’s Power House. This winter, after months of work to plumb, wire, and test the machine, it was lit for the first time and began providing heat to Rockefeller ...
When zombies take over the brain 
Research on Parkinson’s has taken a surprising twist. A group of neurons long assumed to expire in the disease were recently found to not be dead after all—providing a possible explanation for how the condition worsens.
Rockefeller grants commercial license for the development of new HIV drugs
The novel compounds are based on so-called broadly neutralizing antibodies, molecules that make rare people's immune systems capable of fighting HIV. They could potentially yield new treatment and prevention approaches benefitting people around the world, including in developing countries.
The Tri-Institutional Therapeutics Discovery Institute renews partnerships with Takeda and Bridge Medicines
The renewal allows Rockefeller faculty to continue transforming their discoveries into new medicines.
View
View